Recursion Pharmaceuticals continues to have a pipeline of drugs that might provide further validation for the company's platform. See why I rate RXRX a Sell.

Recursion Pharmaceuticals (RXRX) stock gains as the company plans a 20% workforce reduction to streamline operations and extend cash runway to Q4 2027. Read more here.

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Recursion shares jumped over 18% after launching Boltz-2, a breakthrough AI model with MIT that predicts molecular binding The open-source model significantly accelerates drug discovery, making ...

Discover how Alpha Evolve is improving AI with recursive self-improvement, reshaping fields like math, hardware design and efficiency.

Shares of Recursion Pharmaceuticals (RXRX 8.72%) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly.

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning ...

Altitude Lab, a biotech accelerator formed by Recursion, on Wednesday announced the launch of a pre-seed venture fund to support early-stage startups affected by the changes in federal funding policy.

How to Play RXRX Stock Recursion's first-mover advantage in AI-driven drug discovery positions it as a leader in the space, with a strong pipeline focused on Precision Oncology and Rare Diseases.

Is Recursion Pharmaceuticals stock a buy? Does any of this change the premise for buying Recursion Pharmaceuticals stock? Not really. The company's technology is promising.